We have located links that may give you full text access.
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Review
Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
Recurrent depression poses a problem for up to 80% of patients with major depressive disorder (MDD) during their lifetime. Therefore, the optimal treatment goal established by the American Psychiatric Association and the Agency for Health Care Policy and Research is remission and virtual elimination of symptoms. Patients who have a high risk of recurrence often require maintenance therapy and long-term treatment. As a result, identification of antidepressants that are effective in maintaining remission in patients over the long-term and have acceptable tolerability profiles is important. The efficacy of antidepressants in conferring full remission and long-term recovery is an important priority for clinicians. Both selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have been examined for use in long-term treatment of MDD. Recently, 2 long-term (6 to 12 months), double-blind, placebo-controlled studies have shown that venlafaxine is effective in preventing relapse and recurrence. While long-term, head-to-head studies comparing SNRIs with SSRIs are rare, a recent open-label study compared venlafaxine to 4 SSRIs (fluoxetine, paroxetine, sertraline, or citalopram) in outpatients with MDD. The results show that the SNRI venlafaxine is comparable to the SSRIs in terms of remission rates, and venlafaxine may bring patients to remission earlier than SSRIs. Long-term treatment at maximally tolerated doses is also associated with similar incidence of common adverse events between venlafaxine and placebo and tolerability comparable to SSRIs. Thus, there is increasing evidence that venlafaxine and SSRIs are effective and well tolerated in long-term therapy. While it is unclear from the data if continued treatment with SNRIs confers advantages over SSRIs due to an early onset of remission, further studies will provide valuable insights into the efficacy of SNRIs and SSRIs in maintenance therapy.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app